Results 41 to 50 of about 2,572,587 (193)

Immediate and Late Onset Forms of Insulin Hypersensitivity Presenting with Glucose Dysregulation

open access: yesEndocrinology Research and Practice, 2018
We report the case of a 35-year-old woman allergic to detemir, neutral protamine Hagedorn, and glargine. Initially, local reactions to the insulin preparations occurred, which continued even after the types of insulin and the application areas were ...
Ceyda TUNAKAN DALGIÇ   +4 more
doaj  

Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke

open access: yesNeuropsychiatric Disease and Treatment, 2022
Lin-Zhe Du, Pei-Yan Liu, Chen-Yan Ge, Yang Li, Yuan-Yuan Li, Mu-Fei Tang, Jin-Jin Chen Department of Clinical Pharmacy, Nanjing First Hospital, Nanjing, People’s Republic of ChinaCorrespondence: Jin-Jin Chen, Department of Clinical Pharmacy, Nanjing ...
Du LZ   +6 more
doaj  

ОСОБЕННОСТИ НЕВРОЛОГИЧЕСКИХ ПРОЯВЛЕНИЙ САХАРНОГО ДИАБЕТА 1-го ТИПА ПРИ ИСПОЛЬЗОВАНИИ РАЗНЫХ МЕТОДОВ ИНСУЛИНОТЕРАПИИ

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2015
The study aimed to examine the features of neurological manifestations of diabetes mellitus type 1 by using insulin therapy with continuous subcutaneous infusion and multiple subcutaneous injections.

doaj  

The 12 month impact of continuous insulin infusion therapy on glycaemic control in adults with type 1 diabetes, at the Townsville hospital, Queensland - A retrospective study

open access: yesSri Lanka Journal of Diabetes Endocrinology and Metabolism, 2019
Aims: The purpose of this study was to assess the impact of continuous subcutaneous insulin infusion therapy (CSII) on glycosylated haemoglobin level (HbA1c), total daily dose of insulin (TDD), weight, episodes of diabetic ketoacidosis (DKA), severe ...
Suji Prabhaharan   +2 more
doaj   +1 more source

Efficiency of Continuous Subcutaneous Insulin Infusion for Premature Neonate: A Case Report

open access: yes, 2022
Neonatal hyperglycaemia is common in extremely low birth weight (ELBW, <1,000 g) infants, associated with a number of adverse clinical outcomes, and usually treated with continuous intravenous insulin infusion (CIVII). We report a case of continuous
Soleirol, Marion   +13 more
core   +1 more source

Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations

open access: yesJournal of Pharmaceutical Health Care and Sciences, 2019
Background Multiple daily subcutaneous injections (MDSIs) are mainly used for formulating an insulin therapy for diabetic patients; however, they also cause insulin-derived amyloidosis (IDA) and lead to poor glycemic control.
Yui Ohno   +7 more
doaj   +1 more source

Patient management of long-term continuous subcutaneous insulin infusion

open access: yes, 2005
AIM: This paper reports a study of patients' current practice with continuous subcutaneous insulin infusions, particularly with respect to the management of the pump.
Wredling, Regina,   +7 more
core   +1 more source

Overcoming marked insulin resistance in a patient with type 2 diabetes mellitus by means of insulin pumptherapy

open access: yesСахарный диабет, 2012
Patients with type 2 diabetes mellitus (T2DM) often feature resistance to endogenous and exogenous insulin which is a serious problemto overcome. Current paper presents clinical case of T2DM characterized by marked insulin resistance, where high dosage ...
Ekaterina Viktorovna Artemova   +3 more
doaj   +1 more source

Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection

open access: yes, 2015
Improved glycemic control is the only\ud treatment that has been shown to be\ud effective for diabetic peripheral neuropathy\ud in patients with type 1 diabetes (1).\ud Continuous subcutaneous insulin infusion\ud (CSII) is superior to multiple daily ...
Fadavi, Hassan   +16 more
core   +1 more source

Home - About - Disclaimer - Privacy